Background {#Sec1}
==========

Lung and colon cancer are the leading cause of death over all cancers in the United States in 2017, with 155,870 and 50,260 deaths, respectively \[[@CR1]\]. Prognostic signatures and risk stratification are vital to clinical decision making of treatment options in cancer precision medicine. As patient prognosis remains poor \[[@CR2]\], researchers are seeking to develop improved prognostic signatures using molecular information, such as incorporating long non-coding RNA expression \[[@CR3], [@CR4]\].

However, incorporating somatic mutation profiles into prognostic signatures has remained a challenge and is often overlooked due to the sparse and binary nature of somatic mutation data \[[@CR5]\]. The sparsity of the data arises from the observation that the vast majority of mutated genes are not shared among patients \[[@CR6]\]. Save for a few frequently mutated driver genes, most somatically mutated genes are likely to be composed of only passenger mutations that do not provide growth advantage \[[@CR7]\].

To investigate the prognostic value of somatic mutations, studies have chosen to tackle the challenge by confronting the sparsity problem. Le Morvan et al. \[[@CR8]\] uses gene-gene networks as prior knowledge to de-sparsify the data. A patient's binary somatic mutation profile is transformed by removing non-essential mutations and adding proxy mutations based on gene-gene network topology to normalize tumor mutational burden within a sample of patients. However, gene-gene networks vary from tissue to tissue and a single set of canonical gene-gene networks as prior knowledge may omit or overemphasize some interactions \[[@CR9]\]. To address this issue, other studies have elected to use cancer-specific co-expression networks based on RNA expression data \[[@CR10]\] or canonical pathways \[[@CR11]\].

In this study, we confront the challenge of the binary nature of somatic mutation data rather than the sparsity problem. We propose the usage of the quantitative mutation frequency ratio of tumor vs. normal tissue from whole exome sequencing in building somatic mutation profiles. Using somatic mutation data for lung adenocarcinoma (LUAD) and colorectal adenocarcinoma (COAD) from The Cancer Genome Atlas (TCGA) \[[@CR12], [@CR13]\], we evaluate the risk stratification and prognostic performance of somatic mutation signatures generated by using two types of continuous somatic mutation profiles: mutation frequency ratio (MFR) profiles and tumor mutation frequency (TMF) profiles. We compare to two existing types of binary mutation profiles, raw binary mutation (BM) profiles and gene-gene network normalized profiles provided by NetNorM \[[@CR8]\]. We show that the somatic mutation signatures generated by MFR profiles consistently provides statistically significant risk stratification while the other types of profiles do not.

Results {#Sec2}
=======

Identification of prognostic somatically mutated genes {#Sec3}
------------------------------------------------------

To identify and evaluate prognostic somatically mutated genes using different types of somatic mutation profiles, we used a pipeline (Fig. [1](#Fig1){ref-type="fig"}) adapted from Shukla et al.'s RNA-seq pipeline \[[@CR3]\]. Clinical and controlled somatic mutation data for LUAD and COAD was gathered from TCGA \[[@CR12], [@CR13]\]. The data (Table [1](#Tab1){ref-type="table"}) was partitioned randomly into training (*n* = 328 for LUAD and *n* = 286 for COAD) and validation (*n* = 167 for LUAD and *n* = 141 COAD) datasets and somatic mutation profiles generated.Fig. 1Identification of prognostic somatic mutation gene signature. DNA-seq prognostic analysis and signature generation pipeline. TCGA somatic mutation data is randomly split into training and validation datasets. Univariate Cox analysis identifies mutated genes associated with survival and only significant genes (FDR ≤ 0.05) are considered further. Bidirectional stepwise model selection for multivariate Cox analysis is used to select the final prognostic somatic mutation gene signature. Risk scores for patients in both training and datasets are computed using the final signature. The 75% percentile risk score of the training dataset is used as the stratification threshold for the KM analysis on both the training and validation datasetsTable 1Clinical characteristics of the patientsFactorTCGA LUAD TrainingTCGA LUAD ValidationTCGA COAD TrainingTCGA COAD ValidationNum. of patients328167286141Age, years, mean (SD)65.8 (10.2)64.5 (9.6)66.6 (12.8)66.4 (13.5)Median survivor follow-up, days506.5218.0716.5730.0Female, num. (%)169 (51.5)97 (58.1)151 (52.8)52 (36.9)Stage I, num. (%)176 (53.7)90 (54.0)50 (17.5)22 (15.6)Stage II, num. (%)77 (23.5)39 (23.4)101 (35.3)62 (44.0)Stage III, num. (%)49 (14.9)31 (18.6)75 (26.2)44 (31.2)Stage IV, num. (%)21 (6.4)5 (3.0)50 (17.5)12 (8.5)

Four different types of somatic mutation profiles were considered: MFR, TMF, BM, and NetNorM profiles. The somatic mutation profile of a single patient is a vector with an element for every gene. The BM profile of a patient consists of a sparse binary vector where an element denotes if a gene is somatically mutated or not. The NetNorM profile was generated from the BM profile by normalizing the number of mutated genes via the removal or addition of somatically mutated genes \[[@CR8]\]. While the NetNorM profile remains binary in nature, its process mitigates the sparsity problem of somatic mutation data by incorporating gene-gene network prior knowledge.

Additionally, we propose the usage of MFR and TMF profiles, which to the best of our knowledge, has not be considered previously in the literature to confront the difficulties of working with sparse binary data. TMF profiles incorporate the tumor data on the number of reads supporting the mutation vs. the reference genome. The MFR takes it a step further and considers the mutation frequency ratio of the tumor sample vs. the paired normal tissue sample. Both TMF and MFR profiles use continuous rather than binary values for somatic mutation profile representation.

Individually for each type of somatic mutation profile and tumor type, somatic mutation based prognostic signatures are generated using the pipeline outlined in Fig. [1](#Fig1){ref-type="fig"}. Univariate Cox proportional hazards regression is first performed on the training dataset to short list prospective genes with a FDR cutoff of 0.05. The prospective genes are then subjected to bidirectional stepwise multivariate Cox proportional hazards regression model selection to the determine the final prognostic signature (Table [2](#Tab2){ref-type="table"} and Table [3](#Tab3){ref-type="table"}). We verified that all of the final prognostic signatures do not violate the proportional hazards assumption using the Schoenfeld Residual Test.Table 2Genes found in prognostic somatic mutation gene signatures for LUADGene SymbolMFRTMFBMFNetNorMABCB6TRUEFALSETRUEFALSEMSANTD3TRUEFALSEFALSEFALSECFAP69TRUEFALSEFALSEFALSECHST5TRUEFALSEFALSEFALSEZNF768TRUEFALSEFALSEFALSENDNTRUEFALSEFALSEFALSESERPINI2TRUEFALSEFALSEFALSEFGD3TRUETRUETRUETRUESLC29A4TRUETRUETRUEFALSEHSD17B4TRUETRUETRUEFALSEOR5H15TRUEFALSETRUEFALSEPFKMTRUEFALSEFALSEFALSEMADDTRUEFALSEFALSEFALSEPODNTRUEFALSETRUEFALSEMMP8TRUETRUEFALSEFALSEARHGAP4TRUEFALSEFALSEFALSESDHATRUETRUETRUEFALSEC3orf20TRUEFALSEFALSEFALSEHEATR1TRUEFALSEFALSEFALSEMYOTTRUEFALSEFALSEFALSEAOC1FALSETRUETRUEFALSETLR9FALSETRUEFALSEFALSEMOSPD2FALSETRUETRUETRUEEPHA2FALSETRUETRUETRUEZNF880FALSETRUEFALSEFALSETAS2R39FALSETRUEFALSEFALSEDNTTIP1FALSETRUEFALSEFALSEHHATFALSETRUETRUEFALSEALOXE3FALSETRUETRUEFALSEPRMT5FALSETRUETRUEFALSEFAM83BFALSETRUEFALSEFALSEBEST4FALSETRUEFALSEFALSEBCAS3FALSETRUEFALSEFALSEMAP3K1FALSETRUEFALSEFALSEGPR52FALSETRUEFALSEFALSEDNAJC10FALSETRUEFALSEFALSEADGRG7FALSETRUEFALSEFALSECDRT15FALSETRUEFALSEFALSEMOCS3FALSETRUEFALSEFALSEC5FALSETRUEFALSEFALSECNTN1FALSETRUEFALSEFALSECLCN2FALSETRUEFALSEFALSECBLBFALSETRUETRUETRUEMSH3FALSETRUEFALSEFALSERBM45FALSETRUEFALSEFALSESQRDLFALSEFALSETRUEFALSELIPEFALSEFALSETRUEFALSETBPL2FALSEFALSETRUEFALSELANCL2FALSEFALSETRUEFALSEBMP6FALSEFALSETRUEFALSETTLL4FALSEFALSETRUEFALSENPAS1FALSEFALSETRUEFALSEALX4FALSEFALSETRUEFALSECRNNFALSEFALSETRUEFALSELRRC4FALSEFALSETRUEFALSENPC1L1FALSEFALSETRUETRUETYRO3FALSEFALSEFALSETRUETOP2AFALSEFALSEFALSETRUESIGLEC10FALSEFALSEFALSETRUEAQP6FALSEFALSEFALSETRUEZC3H7BFALSEFALSEFALSETRUEIGHG2FALSEFALSEFALSETRUETTI1FALSEFALSEFALSETRUEMEGF10FALSEFALSEFALSETRUETRIM8FALSEFALSEFALSETRUEZNF714FALSEFALSEFALSETRUEFOXO4FALSEFALSEFALSETRUEOR3A1FALSEFALSEFALSETRUECOL24A1FALSEFALSEFALSETRUECOPEFALSEFALSEFALSETRUEPCDH7FALSEFALSEFALSETRUESLC25A24FALSEFALSEFALSETRUEFUT9FALSEFALSEFALSETRUEMAGI2FALSEFALSEFALSETRUEZNF148FALSEFALSEFALSETRUEBAZ2BFALSEFALSEFALSETRUEList of somatically mutated genes selected by the pipeline for LUAD using each type of somatic mutation profilesTable 3Genes found in prognostic somatic mutation gene signatures for COADGene SymbolMFRTMFBMFNetNorMABCB5FALSEFALSEFALSETRUEACSM5FALSEFALSEFALSETRUEARHGAP15TRUEFALSEFALSEFALSEC11orf53TRUEFALSEFALSEFALSEC8BFALSEFALSETRUETRUECAPN9FALSETRUEFALSEFALSECARD11FALSEFALSEFALSETRUECDH24TRUEFALSETRUEFALSECER1TRUETRUETRUEFALSECHI3L1TRUEFALSEFALSEFALSECOG7TRUEFALSEFALSEFALSECOL4A4FALSETRUEFALSEFALSECOL9A1FALSEFALSEFALSETRUECTGLF11PFALSETRUEFALSEFALSEDCAF12FALSETRUEFALSEFALSEDGKBFALSEFALSEFALSETRUEDMKNTRUEFALSETRUEFALSEDNALI1TRUEFALSETRUEFALSEDOCK3FALSEFALSEFALSETRUEEIF3FFALSEFALSEFALSETRUEFBXO38TRUEFALSEFALSEFALSEFOXD4L6FALSETRUEFALSEFALSEFSHRFALSETRUEFALSEFALSEGRPRFALSETRUEFALSEFALSEH2AFY2FALSEFALSETRUEFALSEHIF1ANFALSETRUEFALSEFALSEIGHA1TRUEFALSEFALSEFALSEIQCHTRUEFALSEFALSEFALSEKANSL3TRUETRUEFALSEFALSEKRT73FALSEFALSEFALSETRUEMARCH11TRUEFALSETRUEFALSEMEOX1TRUEFALSEFALSEFALSEMETTL21CTRUEFALSETRUETRUEMICATRUETRUETRUEFALSENAV1FALSEFALSETRUEFALSENKD1TRUETRUETRUEFALSENTSR1FALSETRUEFALSEFALSEOGFRFALSEFALSEFALSETRUEOR10A7FALSETRUEFALSEFALSEOR10H2FALSEFALSEFALSETRUEOR11H1FALSEFALSEFALSETRUEOR13C8FALSETRUEFALSEFALSEOR1D5FALSEFALSETRUETRUEPDHBTRUEFALSEFALSEFALSEPDPRFALSEFALSEFALSETRUEPRKG2TRUEFALSEFALSEFALSEPSMD2TRUEFALSEFALSEFALSERANBP17TRUEFALSEFALSETRUERARGFALSETRUEFALSEFALSERBM22FALSEFALSEFALSETRUERERGTRUEFALSETRUEFALSERP11.231C14.4TRUEFALSEFALSEFALSESAGE1FALSETRUEFALSEFALSESCD5FALSETRUEFALSEFALSESDR9C7TRUEFALSEFALSEFALSESERPINB3TRUETRUEFALSEFALSESPDYE5FALSETRUEFALSEFALSESUSD2FALSEFALSEFALSETRUETREHFALSEFALSEFALSETRUEUBL4BFALSETRUEFALSEFALSEUBTD1TRUEFALSEFALSEFALSEUBTFL1TRUEFALSEFALSEFALSEUSP50TRUEFALSEFALSEFALSEVPS36FALSEFALSEFALSETRUEWDR7FALSEFALSEFALSETRUEZNF133TRUETRUEFALSEFALSEZNF214TRUETRUETRUEFALSEZNF586TRUEFALSEFALSEFALSEZNF83TRUEFALSEFALSEFALSEList of somatically mutated genes selected by the pipeline for COAD using each type of somatic mutation profiles

Comparison of risk stratification {#Sec4}
---------------------------------

Kaplan-Meier (KM) survival curves are used to assess and compare the different types of somatic mutation profiles in both the training and validation datasets. Using the final Cox model for risk scoring, the high-risk threshold for stratification in both the training and validation datasets was chosen to be the 75th percentile of the risk scores in the training dataset.

We observed that all somatic mutation profile types achieve significant risk stratification on the training dataset (log rank test *p*-value ≈ 0) for both LUAD and COAD (Fig. [2](#Fig2){ref-type="fig"}, Fig. [3](#Fig3){ref-type="fig"}). For both LUAD and COAD, however, only the stratification generated by MFR profiles is statistically significant in the validation datasets (log rank test p-value = 0.0101 for LUAD, 0.0314 for COAD) (Fig. [2](#Fig2){ref-type="fig"}a, Fig [3](#Fig3){ref-type="fig"}a), while all other profiles, including NetNorM, are not statistically significant (Fig. [2](#Fig2){ref-type="fig"}b, c and d, Fig. [3](#Fig3){ref-type="fig"}b, c and d). Furthermore, the final prognostic signatures generated by each type of somatic mutation profile only minimally overlap for both LUAD and COAD cases (Fig. [4](#Fig4){ref-type="fig"}).Fig. 2Kaplan-Meier analysis of prognostic somatic mutation gene signatures. KM survival curves for LUAD training and validation datasets using (**a**) MFR, (**b**) TMF, (**c**) BM, and (**d**) NetNorM somatic mutation profilesFig. 3Kaplan-Meier analysis of prognostic somatic mutation gene signatures. KM survival curves for COAD training and validation datasets using (**a**) MFR, (**b**) TMF, (**c**) BM, and (**d**) NetNorM somatic mutation profilesFig. 4Selected somatically mutated genes for signatures. Venn diagrams of selected genes using MFR, TMF, BM, and NetNorM somatic mutation profiles for (**a**) LUAD and (**b**) COAD

The results suggest that the MFR profile's prognostic signature is more robust, while the other types of profiles are subject to harsh overfitting that is typical in contexts with a larger number of covariates than samples. This is consistent with the observation that NetNorM profiles typically do not perform statistically different from binary profiles \[[@CR8]\]. De-sparsifying somatic mutation data using gene-gene network prior information does not necessarily lead to improved prognostic and risk stratification performance.

Somatic mutation gene signatures {#Sec5}
--------------------------------

A PubMed search of the individual genes and a network analysis of the full signatures using Ingenuity Pathway Analysis (QIAGEN Inc., <https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/>, accessed: Feb. 14, 2018) was performed to assess the biological relevancy of the final prognostic gene signatures generated by MFR profiles. A network containing 16 of the 20 genes in the LUAD prognostic signature (Table [4](#Tab4){ref-type="table"}) was found (Fig. [5](#Fig5){ref-type="fig"}). The network is associated with cell death and survival, and cellular movement. All genes in the prognostic signature are positively associated with risk (denoted in red in Fig. [5](#Fig5){ref-type="fig"}). *SDHA* is the gene with the largest coefficient in the risk model (hazard ratio (HR) = 1.877). *SDHA* is a tumor suppressor and is implicated in paraganglioma and gastrointestinal stromal tumors \[[@CR14]\]. While association of *SDHA* copy number variation to prognosis was found in lung squamous cell carcinoma \[[@CR15]\], we have found no literature exploring the connection of *SDHA* to lung adenocarcinoma.Table 4Prognostic somatic mutation gene signature for LUAD using MFR profilesGeneHRLower .95Upper .95ABCB61.5331.34601.745MSANTD31.1541.00751.321CFAP691.0360.72751.475CHST51.6101.40811.841ZNF7681.5931.36261.861NDN1.1120.98571.254SERPINI21.1871.02891.369FGD31.3791.15871.642SLC29A41.2951.14281.468HSD17B41.3501.17231.556OR5H151.4591.23081.731PFKM1.4061.13411.742MADD1.2561.14841.374PODN1.1530.99721.332MMP81.3961.24291.569ARHGAP41.4211.10781.822SDHA1.8771.38772.538C3orf201.1871.04681.347HEATR11.1321.01231.266MYOT1.1790.96941.433Fig. 5Network for somatically mutated genes in LUAD signature. Network containing 16 of the 20 genes in the LUAD prognostic signature using MFR somatic mutation profiles. The network is associated with cell death and survival, and cellular movement. Red nodes represent genes in the final prognostic signature and denote positive association with risk

Four additional genes in the LUAD signature also have known associations with lung cancer. *PFKM* has mutations associated with survival outcomes in lung squamous cell carcinoma \[[@CR16]\]. *MADD* promotes survival of LUAD cells and is a potential therapeutic target \[[@CR17]\]. *SERPINI2* is tumor suppressor gene and is associated with squamous cell lung cancer \[[@CR18]\]. Finally, it has been found that certain *MMP8* mutations are correlated with risk of developing lung cancer \[[@CR19]\].

Eight of the remaining genes in the LUAD signature are associated with other cancer types and their connection to LUAD is yet uncharacterized. *ABCB6* \[[@CR20], [@CR21]\], *ZNF768* \[[@CR22]\], and the *TP53*-mediated tumor suppressor gene *NDN* \[[@CR23]\] are all associated with colorectal cancers. *MSANTD3* is an oncogene in salivary gland acinic cell carcinoma \[[@CR24]\]. *FGD3* is implicated in breast cancer \[[@CR25]\] and *ARHGAP4* in ovarian tumors \[[@CR26]\]. It has been observed that increased expression of *HSD17B4* is correlated with poor prognosis in prostate cancer \[[@CR27]\]. Lastly, correlation of *HEATR1* with shorter overall survival has been shown in pancreatic ductal adenocarcinoma \[[@CR28]\].

For the COAD prognostic signature (Table [5](#Tab5){ref-type="table"}), we found that 30 of the 32 genes were involved in two different networks. The first network contains 16 of the 32 genes in the COAD prognostic signature (Fig. [6](#Fig6){ref-type="fig"}) and is associated with embryonic, organismal, and tissue development. The second network contains 14 of the 32 genes in the COAD prognostic signature (Fig. [7](#Fig7){ref-type="fig"}) and is associated with cancer and organismal injury and abnormalities. Unlike the LUAD signature where all genes were positively associated with increased risk, mutations in seven of the genes are associated with reduced risk (*USP50*, *UBTD1*, *ZNF83*, *FBX038*, *C11orf53*, *IQCH*, and *CHI3L1*) and are denoted in green in Figs. [6](#Fig6){ref-type="fig"} and [7](#Fig7){ref-type="fig"}.Table 5Prognostic somatic mutation gene signature for COAD using MFR profilesGeneHRLower .95Upper .95DNALI11.53291.15952.0266CDH241.89021.58052.2607MICA1.88271.46792.4147METTL21C1.41211.24691.5993IGHA11.88581.55622.2851UBTFL12.30071.75953.0083PSMD21.32161.14311.5280CER11.30711.13961.4994RERG1.95451.30252.9327ZNF2141.50771.21891.8650MARCH111.43031.22571.6689USP500.76400.58051.0056NKD11.82101.45792.2744UBTD10.48350.31060.7526MEOX11.41011.24151.6017KANSL31.24961.08961.4330ARHGAP151.23901.10331.3913SERPINB31.37681.18081.6053ZNF830.41530.31690.5443DMKN1.41731.24791.6097RP11.231C14.43.38552.37634.8232SDR9C71.39401.17021.6607PRKG21.26191.10851.4365RANBP171.29591.16051.4471COG71.17591.03451.3367FBXO380.64750.51960.8068PDHB1.89351.48852.4086ZNF1331.43021.19481.7119C11orf530.73420.56430.9551IQCH0.86540.73851.0141CHI3L10.24790.13380.4591ZNF5861.21461.03221.4291Fig. 6First network for somatically mutated genes in COAD signature Network containing 16 of the 32 genes in the COAD prognostic signature using MFR somatic mutation profiles. The network is associated with embryonic, organismal, and tissue development. Red and green nodes represent genes in the final prognostic signature and denote positive and negative association with risk, respectivelyFig. 7Second network for somatically mutated genes in COAD signature Network containing 14 of the 32 genes in the COAD prognostic signature using MFR somatic mutation profiles. The network is associated with cancer and organismal injury and abnormalities. Red and green nodes represent genes in the final prognostic signature and denote positive and negative association with risk, respectively

Ten of the genes in the COAD signature are implicated in colorectal cancers (CRC). *MICA* has high cell-surface expression in cancers of the digestive system and have been found to be correlated with increased survival \[[@CR29]\]. Copy number variation of *RERG* is correlated with CRC risk \[[@CR30]\]. *NKD1* is involved in Wnt signaling central to tumor cell growth in CRC and other cancers \[[@CR31]\]. Lower expression of *UBTD1* correlates with worse prognosis \[[@CR32]\]. *SERPINB3* has a driving role in more aggressive cellular phenotypes of CRC \[[@CR33]\]. *DMKN* has been previously proposed as a biomarker of early-stage CRC \[[@CR34]\]. *PDHB* diminishes the oncogenic effects of *miR-146b-5p* on the growth and invasion of CRC \[[@CR35]\]. *C11orf53* is a potential gene involved in CRC etiology \[[@CR36]\]. *CHI3L1* promotes macrophage recruitment and angiogenesis in CRC \[[@CR37]\]. Lastly, alterations of *CDH24* contribute to tumorigenesis, as *CDH24* is important to the maintenance of cell adhesion \[[@CR38]\].

Another nine genes of the COAD signature have known associations with other types of cancers, but not with CRC yet. *DNALI1* \[[@CR39]\] and *MEOX1* \[[@CR40]\] are associated with breast cancer. In particular, *MEOX1* is correlated with poor survival of breast cancer patients. *MARCH11* has been used as a biomarker in a methylation panel for early cancer detection and prognosis prediction in non-small cell lung cancer \[[@CR41]\]. *ARHGAP15* is correlated with survival in early-stage pancreatic ductal adenocarcinoma \[[@CR42]\]. *IGHA1* is associated with gastric tumorigenesis \[[@CR43]\]. *CER1* is associated with glioma \[[@CR44]\]. *SDR9C7* promotes lymph node metastasis in esophageal squamous cell carcinoma \[[@CR45]\]. *PRKG2* is associated with acute mast cell leukemia \[[@CR46]\]. Finally, *ZNF133* is potential biomarker for osteosarcoma \[[@CR47]\].

Discussion {#Sec6}
==========

Cancer genomic data is increasingly becoming a hot topic in precision cancer medicine research, including the identification of therapeutic targets, biomarker-based clinical trials, and the study of genomic determinants of therapy response \[[@CR48]\]. The signatures found in the present retrospective study are promising and their potential clinical integration should be further investigated with a prospective study.

While the results are promising, there are limitations to this initial work. Demographic and clinical data were not incorporated into the prognostic models. Gene expression data is also available for TCGA LUAD and COAD datasets. Integration of all data types could potentially improve prognostic and risk stratification performance and provide further biological insights. Furthermore, all types of cancer in TCGA should be analyzed for a future pan-cancer study.

The present study was also done at the gene level. There is potential that specific mutations to a gene may have different prognostic effects. However, with the sample size of TCGA data, it is not feasible to observe statistically significant results due to the increased sparsity of somatic mutation data at the specific mutation level. Further data or methods to mitigate the increased sparsity is required for further study.

The present work demonstrated the robustness of prognostic signatures using MFR profiles within TCGA LUAD and COAD VarScan-based somatic mutation data \[[@CR49]\] by the partitioning of the data into training and validation datasets. As a result, the experimental and analysis protocols are consistent. The robustness with respect to different somatic mutation calling software within TCGA should be conducted, as calls from MuSE \[[@CR50]\], MuTect \[[@CR51]\], and SomaticSniper \[[@CR52]\] are provided in addition to VarScan. Furthermore, the methods robustness to data generated from different experimental protocols, such as by investigating data generated by different institutions and projects, should be studied in the future.

Conclusions {#Sec7}
===========

To improve clinical tools and biological understanding of LUAD and COAD, we demonstrated a methodology to generating robust prognostic somatic mutation-based gene signatures. We demonstrated the robustness of MFR profiles and its potential to be a powerful prognostic tool in cancer, unlike other alternative types of somatic mutation profiles, TMF, BM, and NetNorM, that did not achieve statistically significant risk stratification in validation datasets. The genes selected by the methodology using MFR profiles was shown to be biologically relevant and has potential for use in effective management LUAD and COAD.

Methods {#Sec8}
=======

Somatic mutation data and profiles {#Sec9}
----------------------------------

Controlled TCGA somatic mutation data (VarScan MAF files \[[@CR49]\]) were downloaded from NCI's Genomic Data Commons (<https://gdc.cancer.gov>/, accessed: Feb. 14, 2018) for LUAD and COAD (Project ID 17109, A Pan-Cancer Analysis of Somatic Mutation Profiles for Tumor Immunogenicity and Prognosis). The data were filtered, keeping only missense mutations. The missense mutations were then aggregated into gene level mutation profiles. For BM profiles, the gene is flagged as mutated if it contains any missense mutation.

The NetNorM normalization method was used as a representative of somatic mutation profiles using gene-gene network information \[[@CR8]\]. NetNorM uses networks from Pathway Commons (<http://www.pathwaycommons.org>), which feature an integrated network data of public pathway and interaction databases. The user-specified parameter for NetNorM is the target number of mutated genes *k*. This parameter is set to the median number of mutated genes in the training dataset, which is 193 and 151 for LUAD and COAD, respectively. NetNorM ranks genes based on their mutation status and network connectedness. A patient's somatic mutation profile is normalized by setting only the top *k* genes as being mutated. Since mutated genes are always ranked higher than non-mutated genes, patients with more than *k* mutated genes will have lower ranked mutated genes set to unmutated, while patients with less than *k* mutated genes will obtain artificial proxy mutated genes.

Mutation frequency ratio and tumor frequency profiles {#Sec10}
-----------------------------------------------------

For patient *i*, the MAF files contain the number of reads supporting the reference allele for mutation *j*, *TRC*~*ij*~ and *NRC*~*ij*~ for tumor and normal samples, respectively. Analogously, denote the number of reads supporting the alternate allele, *TAC*~*ij*~ and *NAC*~*ij*~ for tumor and normal samples, respectively. The tumor and normal sample mutation frequencies, *TMF*~*ij*~ and *NMF*~*ij*~, are computed using Eqs. ([1](#Equ1){ref-type=""}) and ([2](#Equ2){ref-type=""}), respectively. The mutation frequency ratio *MFR*~*ij*~ is then simply the ratio of the tumor to normal sample mutation frequencies. To generate a patient's gene level MFR and TMF profiles, the mutations are aggregated by gene using the mean ratio or frequency within that gene.$$\documentclass[12pt]{minimal}
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Signature generation and statistical analysis {#Sec11}
---------------------------------------------

TCGA clinical data were downloaded from NCI's Genomic Data Commons (<https://gdc.cancer.gov>**/**, accessed: Feb. 14, 2018) for LUAD and COAD. These data were partitioned randomly into training (*n* = 328 for LUAD and *n* = 286 for COAD) and validation (*n* = 167 for LUAD and *n* = 141 COAD) datasets. Rarely mutated genes in somatic mutation profiles were omitted when less than 1% of patients in a sample have the mutation. MFR and TMF profiles, which are continuous valued, were *log2* transformed. Univariate Cox proportional hazards regression was used to assess association with overall survival using R survival package (R v3.4.0, survival v2.41--3) with a Benjamini-Hochberg FDR cutoff of 0.05. Multivariate Cox proportional hazards regression was performed using bidirectional stepwise model selection with the R MASS package (MASS v7.3--47). Kaplan-Meier analysis was used to assess risk stratification with R survival and GGally packages (GGally v1.3.2). Pathway and network analysis weres performed with Ingenuity Pathway Analysis.
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